Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial
{{output}}
Background: Peri-operative immunotherapy, particularly anti-programmed cell death protein-1 therapy, combined with neoadjuvant chemotherapy has emerged as one of the standard-of-care options for resectable non-small cell lung can... ...
